ALK and non-small cell lung carcinoma: The ALTA-1L study was conducted as an open-label phase III, international randomized trial, where the efficacy of brigatinib was compared to crizotinib in a large patient cohort (n = 275) with ALK-positive NSCLC, with all patients being naïve to ALK-TKI treatment [69].